NANOBIOTIX to Participate in Investor Conferences in March

NANOBIOTIX, a late-stage biotechnology company identified by its ticker symbols Euronext: NANO and NASDAQ: NBTX, has announced its participation in several key investor conferences throughout March 2026. Specialized in pioneering nanotherapeutic approaches for cancer treatment and other major diseases, the company aims to engage with the investment community to showcase its innovative solutions and business prospects.

The series of conferences includes the TD Cowen's Health Care Conference on March 4 in Boston, where Laurent Levy, the CEO, along with Bart van Rhijn, Chief Financial & Business Officer, will participate in a fireside chat at 11:10 AM ET. Following this, NANOBIOTIX will attend the UBS Biotech Summit and the Jefferies Biotech on the Beach Summit on March 9 and 10, respectively, both located in Miami Beach, FL. Additionally, the company will feature at the Leerink's Global Healthcare Conference on March 11, with another fireside chat scheduled at 2:20 PM EDT.

Founded in 2003 and headquartered in Paris, France, NANOBIOTIX has been committed to advancing treatment options and enhancing patient outcomes through its unique, physics-based therapeutic methodologies. The company has established a robust patent portfolio encompassing over 25 families related to three major nanotechnology platforms: oncology, bioavailability and biodistribution, and central nervous system disorders. Listed on Euronext Paris since 2012 and on Nasdaq since 2020, NANOBIOTIX continues to push the boundaries of scientific innovation with the goal of ultimately improving the quality of life for patients worldwide.

Investors can learn more about NANOBIOTIX on their official website or through their communications and investor relations contacts.

As Nanobiotix (Euronext: NANO; NASDAQ: NBTX) prepares for its series of upcoming investor conferences in March, market participants should consider the implications of its active engagement with the investment community. The company, a late-stage clinical biotechnology innovator, is at a critical juncture in its growth trajectory, particularly in the realm of novel nanotherapeutic treatments for cancer and major diseases.

Participation in high-profile conferences like TD Cowen's Health Care Conference and the UBS Biotech Summit could serve as a strategic move to enhance investor interest and confidence. The leadership team, including CEO Laurent Levy and CFO Bart van Rhijn, will provide insights into their advancements in clinical trials and the potential for future breakthroughs tailored to improve patient outcomes. Investors should be attuned to the messaging around the company’s proprietary nanotechnology platforms, particularly in oncology, as this could inform future revenue streams.

Nanobiotix's unique positioning in the market, evidenced by over 25 patent families, underscores its commitment to innovation within its core therapeutic areas. This upcoming wave of presentations offers a chance for the management team to elaborate on progress, address investor concerns, and highlight partnerships that may be in the pipeline.

Potential investors should closely monitor these events for potential strategic announcements or new data releases that could significantly affect stock performance. Given the growth potential in the biotechnology sector, particularly amid increased global focus on personalized medicine, Nanobiotix's activities in March could prove pivotal.

As the landscape shifts, maintaining an eye on Nanobiotix's capital markets engagement and clinical development milestones will be crucial for making informed investment decisions in this dynamic sector. Regular assessment of market sentiment and evaluation of scientific advancements will be essential as the company positions itself for potential success in an evolving industry.